Novello

Novello Therapeutics is an Australian biotechnology company specializing in the development of RNA-based therapies for aggressive cancers, particularly glioblastoma. The company utilizes a proprietary discovery platform to identify long non-coding RNAs (lncRNAs) that are essential for tumor growth and survival but are not expressed in healthy tissue. By targeting these lncRNAs with antisense oligonucleotides, Novello aims to create highly specific treatments that overcome the limitations of current oncology standards. Spun out from the University of Queensland and QIMR Berghofer Medical Research Institute, the company is currently advancing its lead candidates through pre-clinical development. Its approach represents a novel frontier in precision medicine, focusing on the "dark matter" of the genome to treat previously undruggable targets.